The clinical effect of MOM (9, 3-di-o-acetyl midecamycin) was evaluated in 10 cases of acute purulent otitis media and 12 cases of acute lacunar tonsilitis. The MOM levels in the serum were assessed 0.5, 1.0, 3.0, 4.5 and 6.0 hours after oral administration of 200mg of MOM, and its levels in the tonsillar tissue were also assessed 1.0 to 3.0 hours after that administration.
The following results were obtained.
1) Satisfactory effects were obtained in 50% of the patients with acute purulent otitis media and 67% of those with acute lacunar tonsillitis.
2) No side effect was observed except in only one patient who showed slight GOT and GPT elevation one week after the treatment. He had had a history of chronic liver disease of several years' duration, and the elevated values were not necessarily attributed to the drug administration.
3) In most cases, serum levels of MOM showed a peak 30 to 60 minutes after administration. But the peak was seen 3.0 to 4.5 hours after administration in a few cases. The average level in the serum was 639.11ng/ml. In some cases, its level was more than 1, 000ng/ml.
4) Good transmigration into the tonsil was proved in all of the cases, and the average tonsillar concentration was 370ng/g.
5) From the results of this series, MOM seems to be a useful drug in the treatment of acute purulent otitis media and acute lacunar tonsillitis, particularly in mild or moderate cases without other basic diseases.
View full abstract